Condition
Allergen Immunotherapy
Total Trials
4
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
1Total
P 1 (1)
Trial Status
Not Yet Recruiting1
Completed1
Recruiting1
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07726147Phase 1RecruitingPrimary
Phase 1, First in Human (FIH), Open-Label, Single-Arm, Ascending Dose Study to Assess the Safety, Tolerability and Preliminary Immunogenicity of ITI-9001 in Japanese Patients With Japanese Red Cedar (JRC) Pollinosis
NCT06330974Not Yet Recruiting
Allergy, Asthma, and Atopic Eczema in Finland
NCT05009134Unknown
Influences of Allergic Rhinitis and Allergen Immunotherapy on SARS-CoV-2 Vaccination
NCT04038268CompletedPrimary
Criteria Used by Health Professionals on the Selection of Allergen Immunotherapy in Real Clinical Practice
Showing all 4 trials